124 related articles for article (PubMed ID: 8069187)
21. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.
Rizzoli V; Carella AM; Carlo-Stella C; Mangoni L
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():76-8. PubMed ID: 2202474
[No Abstract] [Full Text] [Related]
22. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):221-5. PubMed ID: 12136944
[TBL] [Abstract][Full Text] [Related]
23. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia.
Maung ZT; Hogarth L; Reid MM; Proctor SJ; Hamilton PJ; Hall AG
Leukemia; 1994 Sep; 8(9):1487-91. PubMed ID: 8090028
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotype predicts radiation resistance in T-lineage acute lymphoblastic leukemia and T-lineage non-Hodgkin's lymphoma.
Uckun FM; Song CW; Nesbit M; Kersey JH; Ramsay NK
Int J Radiat Oncol Biol Phys; 1992; 24(4):705-12. PubMed ID: 1429095
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
27. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
28. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
30. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
31. Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group.
Rizzoli U; Mangoni L; Carella AM; Aglietta M; Porcellini A; Coleselli P; Angrilli F; Alessandrino EP; Madon E; Locatelli F
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():190-4. PubMed ID: 2653502
[No Abstract] [Full Text] [Related]
32. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
Kramer B; Makrynikola V; Bradstock K
Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
[No Abstract] [Full Text] [Related]
33. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
34. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
35. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Jacob E; Scorsone K; Blaney SM; D'Argenio DZ; Berg SL
Pediatr Blood Cancer; 2008 Apr; 50(4):757-60. PubMed ID: 17849472
[TBL] [Abstract][Full Text] [Related]
36. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
37. Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow.
Becher R; Becker G; Schmidt CG
Haematol Blood Transfus; 1990; 33():133-6. PubMed ID: 2323626
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
Botzler C; Kis K; Issels R; Multhoff G
Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
[TBL] [Abstract][Full Text] [Related]
39. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
40. [Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia].
Tolomeo M; Luparello M; Caravello E; Musso M; Abbadessa V; Perricone R; Cajozzo A
Ann Ital Med Int; 1990; 5(4 Pt 1):341-7. PubMed ID: 2093359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]